Cover Image
市場調查報告書

鐮狀細胞貧血相關的血管閉塞症:開發中產品分析

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361630
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
鐮狀細胞貧血相關的血管閉塞症:開發中產品分析 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 88 Pages
簡介

本報告提供全球各國鐮狀細胞貧血相關的血管閉塞症之治療藥開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,並彙整主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 鐮狀細胞貧血相關的血管閉塞症概要
  • 治療藥的開發
    • 鐮狀細胞貧血相關的血管閉塞症的開發中產品:概要
  • 各企業開發中的治療藥
  • 開發中產品的概要
    • 後期階段的產品
    • 臨床實驗階段的產品
    • 初期階段的產品
  • 各企業開發中的產品
  • 開發治療藥的企業
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Complexa, Inc.
    • Dilaforette AB
    • Gilead Sciences, Inc.
    • Mast Therapeutics, Inc.
    • Pfizer Inc.
    • Seattle Genetics, Inc.
    • Selexys Pharmaceuticals Corporation
  • 治療藥的評估
    • 單劑治療藥的情況
    • 標的別
    • 各作用機制
    • 投藥各途徑
    • 各分子類型
  • 藥物簡介
    • Apixaban (凝血因子Ⅹa抑制劑)
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • CXA-10
    • NVX-508
    • regadenoson
    • rivipansel sodium
    • SelG-1
    • sevuparin sodium
    • SGD-2083
    • ticagrelor
    • vepoloxamer
  • 近幾年的開發平台趨勢
  • 開發暫停的計劃
  • 中止開發的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC8132IDB

Summary

Global Markets Direct's, 'Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2016', provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease
  • The report reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutics and enlists all their major and minor projects
  • The report assesses Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease Overview
  • Therapeutics Development
    • Pipeline Products for Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics under Development by Companies
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Products under Development by Companies
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Bristol-Myers Squibb Company
    • Complexa, Inc.
    • Dilaforette AB
    • Gilead Sciences, Inc.
    • Mast Therapeutics, Inc.
    • Pfizer Inc.
    • Seattle Genetics, Inc.
    • Selexys Pharmaceuticals Corporation
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • apixaban - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CXA-10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVX-508 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • regadenoson - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rivipansel sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SelG-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sevuparin sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGD-2083 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ticagrelor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vepoloxamer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Recent Pipeline Updates
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development Milestones
    • Featured News & Press Releases
      • Feb 22, 2016: Mast Therapeutics Completes Patient Enrollment In Pivotal Phase 3 "EPIC" Study For The Treatment Of Sickle Cell Crisis
      • Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
      • Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology
      • Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
      • Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015
      • Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting
      • Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel
      • Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070)
      • May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial
      • Sep 13, 2013: GlycoMimetics Announces EMA's Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by AstraZeneca Plc, H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Complexa, Inc., H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Dilaforette AB, H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Gilead Sciences, Inc., H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Mast Therapeutics, Inc., H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Pfizer Inc., H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Seattle Genetics, Inc., H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Selexys Pharmaceuticals Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics - Recent Pipeline Updates, H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects, H1 2016
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top